Environment
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
StateIdahoEnacted
H 648: INSURANCE – Adds to existing law to establish provisions regarding coverage of anticancer medications under health benefit plans.
BUSINESS COMMITTEE
H 648 status: Enacted — Reported Signed by Governor on March 31, 2026 Session Law Chapter 259 Effective: 07/01/2026 (updated Apr 1, 2026).
Source
OpenStates
Confidence
Low
Analysis basis
OpenStates summary
01
What this bill does
Official summary alongside an AI-generated read on where it stands and why.
Overall Score
72OUT OF 100
Score:72/100 civic fit
Risk:Moderate Risk
Impact:Moderate Impact 50/100
Constitutionality90%
Bipartisan70%
Public opinion85%
Bill summary
What changes
Requires health insurance plans to provide coverage for anticancer medications.
Who is affected
Health insurance plan providers and plan subscribers.
Requirements and enforcement
Insurers must cover costs for specified anticancer medications.
Costs and funding
Potential increase in insurance premiums to offset mandated coverage.
When it takes effect
Effective date is July 1, 2026.
Potential benefits
Improved patient access to critical medication and standardized treatment coverage.
Risks and tradeoffs
Potential for increased insurance costs and administrative overhead.
What is still unknown
Impact on specific out-of-pocket costs, deductibles, and the breadth of the anticancer medication formulary.
02
Impact analysis
✦ AI analysisModeled effects across six domains, estimated from bill text and comparable legislation.
Economy
Positive outlook
60%
Benefits
- Predictable coverage for medical providers
- Improved financial stability for patients
- Standardized benefit offerings
Risks
- Potential for increased insurance premiums
- Administrative compliance costs for insurers
- Shift in actuarial risk models
Society
Positive outlook
75%
Benefits
- Enhanced access to critical cancer medication
- Reduced financial toxicity for families
- Improved health-related quality of life
Risks
- Potential premium increases for subscribers
- Limited flexibility in benefit design
- Risk of insurers narrowing drug formularies
Technology Industry
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
Civic Accountability
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
Public Health & Safety
Positive outlook
80%
Benefits
- Timely initiation of cancer treatment
- Better adherence to medication protocols
- Improved clinical patient outcomes
Risks
- Potential for restrictive formulary management
- Delays in adopting new drug therapies
- Administrative hurdles affecting provider flow
03
How trustworthy & consequential it is
Sourcing already shown above, this is what the analysis found worth flagging.
Source
OpenStates
Official bill text or data from OpenStates.
Confidence
Low
Information is limited or incomplete.
Analysis basis
OpenStates summary
Source used for this bill's analysis.
Source note
Potential for premium increases for health plan members due to the coverage mandate.
Analysis scope
Source provided is a brief summary, not full bill text.
04
Where it stands
Official recordReported Signed by Governor on March 31, 2026 Session Law Chapter 259 Effective: 07/01/2026
- IntroducedComplete
- CommitteeComplete
- Chamber votesComplete
- Final agreementComplete
- GovernorComplete
- EnactedComplete
05
How it affects your district
✦ Personalized
Set your location
Add your district to see how this bill may affect your community and who to contact.
Your Representatives
Your representatives appear here once you add your location.
06
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.